United States Patent 5,560,903: Claim Scope, Expiration, and MRI Contrast-Agent Patent Landscape

U.S. Patent No. 5,560,903 covers methods for converting paramagnetic metal ions into physiologically compatible chelate complexes, including gadolinium, manganese, and iron complexes used to enhance magnetic-resonance imageability. Its independent claims are broad method claims, while dependent claims address chelator classes, ionic form, formulation, concentration, pH, route of administration, and water solubility. The patent is expired and does not create a current blocking right for generic or competing MRI contrast agents.

What does U.S. Patent 5,560,903 protect?

The patent protects a functional concept: chelating a paramagnetic metal ion so that the ion remains sufficiently paramagnetic while becoming physiologically compatible for administration, including use as an NMR or MRI contrast agent.

The principal protected elements are:

Claim group	Subject matter	Scope
Claims 1-2	Chelation of specified paramagnetic ions	Broadest genus claims
Claim 3	Formation of a physiologically compatible paramagnetic chelate effective for MRI	Broad independent method claim
Claim 4	Pharmaceutical formulation with a pharmaceutically acceptable carrier	Formulation limitation
Claims 5-9	Specific metal classes and ions	Lanthanides, transition metals, Gd(III), Mn(II), iron
Claims 10, 14-15	Chelator structures	Aminopolycarboxylic, open-chain, and cyclic chelators
Claims 11-18	Ionic and salt forms	Free acid/base groups, salts, non-salt forms
Claims 19, 22	Molecular architecture	Non-protein-bound and nonionic complexes
Claims 21, 23-30	Human use and dosage-form features	Concentration, pH, route, isotonicity, aqueous and water-soluble products

The patent is technologically broad but commercially indirect. It does not claim a named marketed product such as gadopentetate dimeglumine, gadobutrol, gadoterate meglumine, or gadoxetate disodium by chemical structure. It claims methods that could encompass many such products if the claim elements were satisfied.

How many independent claims does U.S. Patent 5,560,903 have?

The patent has three independent claims: claims 1, 2, and 3.

Claim 1: broad paramagnetic-ion compatibility method

Claim 1 requires:

A paramagnetic ion;
A ligand that is an acyclic or cyclic complexing agent;
Organic nitrogen, phosphorus, oxygen, or sulfur in the ligand;
Chelation that maintains paramagnetism while rendering the ion physiologically compatible.

The metal scope includes:

Lanthanide elements with atomic numbers 57-70;
Transition metals with atomic numbers 21-29, 42, or 44.

This encompasses lanthanum through ytterbium and transition metals including scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, molybdenum, and ruthenium. The claim is not limited to MRI, human use, a pharmaceutical formulation, or a particular administration route.

Claim 2: MRI-focused version of claim 1

Claim 2 narrows the lanthanide group to atomic numbers 58-70 and expressly requires that the complex be effective to enhance NMR imageability of a patient.

This claim is more commercially relevant to MRI contrast agents because it contains a patient-imaging limitation. It excludes lanthanum, atomic number 57, but includes cerium through ytterbium.

Claim 3: broad chelate-complex method

Claim 3 does not expressly require the ligand to contain nitrogen, phosphorus, oxygen, or sulfur, nor does it specify a metal class. It requires:

A paramagnetic ion;
Chelation by a chelating agent;
Formation of a physiologically compatible chelate complex;
Maintenance of sufficient paramagnetism;
Effectiveness in enhancing a patient's NMR imageability.

Claim 3 is therefore the central MRI method claim. Its breadth is offset by its functional language and by the requirement that the method enhance imaging in a patient.

What compounds and metal ions fall within the claim scope?

The most commercially important claimed ion is gadolinium(III), covered expressly by claim 7. The claims also expressly identify manganese(II), iron, and iron(II).

Ion or class	Express claim coverage
Gd(III)	Claim 7
Mn(II)	Claim 8
Iron	Claim 9
Fe(II)	Claim 20
Lanthanides, atomic numbers 58-70	Claims 2 and 5
Transition metals, atomic numbers 21-29, 42, and 44	Claims 2 and 6

The claims can reach both open-chain and macrocyclic chelators. Claim 10 identifies aminopolycarboxylic acids, while claims 14 and 15 separately cover open-chain and cyclic chelating agents.

Examples of product classes potentially within the technical disclosure include:

Gadolinium-DTPA complexes;
Gadolinium-DOTA complexes;
Gadolinium-HP-DO3A complexes;
Gadolinium-DTPA-BMA complexes;
Gadolinium-DTPA derivatives;
Manganese chelates;
Iron-based paramagnetic complexes.

The claims do not require a particular denticity, coordination number, ligand substitution pattern, counterion, relaxivity value, gadolinium concentration, or imaging sequence.

What formulation features are protected?

Claims 4 and 23-30 add pharmaceutical formulation limitations.

The claimed formulation features include:

A pharmaceutically acceptable carrier;
5-250 mmol/L of the chelate complex;
pH of 6.5-8.0;
Oral suitability;
Neural administration suitability;
Intravascular administration suitability;
Isotonicity with blood;
Aqueous-solution form;
Water solubility.

These claims are narrower than claims 1-3 because infringement requires the specified formulation attribute. For example, a formulation containing a covered chelate but having a pH outside 6.5-8.0 would not satisfy claim 24, although it could still implicate another claim.

The concentration limitation in claim 23 is especially relevant to conventional injectable MRI agents. Commercial extracellular gadolinium agents are commonly supplied at approximately 0.5 mmol/mL, equivalent to 500 mmol/L, before administration. That concentration is outside the literal 5-250 mmol/L range of claim 23. However, dilution before administration, a lower-concentration formulation, or a different dosage form could present a different analysis. Claim 23 is not representative of all commercial gadolinium products.

Do the claims cover ionic and nonionic MRI contrast agents?

Yes. The claim set covers multiple ionic configurations.

Claims 11 and 12 create alternatives for the presence or absence of free acid or free base groups. Claim 13 covers salts formed with inorganic or organic acids or bases. Claims 16 and 17 distinguish complexes that are, or are not, also salts with an additional acid or base.

Claim 22 expressly covers a nonionic chelate complex.

This structure matters because MRI contrast agents are sold in several forms:

Ionic chelate salts, such as gadopentetate dimeglumine and gadoterate meglumine;
Neutral or substantially nonionic complexes, such as gadodiamide and gadobutrol;
Complexes with additional counterions or pharmaceutical salts.

The patent therefore attempted to prevent avoidance based solely on salt selection or neutralization state.

What is the patent expiration date?

U.S. Patent 5,560,903 is expired.

The patent issued in 1996. Under the pre-URAA patent-term framework generally applicable to applications filed before June 8, 1995, the ordinary term was 17 years from grant. On that basis, the ordinary term would have ended in 2013, subject to any patent-term adjustment, disclaimer, or extension reflected in the official prosecution record.[1][2]

No current enforceable patent right arises from the claims supplied. The patent cannot be used today to block a generic MRI contrast agent, a new gadolinium formulation, or a competing chelation technology solely on the basis of Patent 5,560,903.

What is the Orange Book status of U.S. Patent 5,560,903?

Patent 5,560,903 has no current Orange Book blocking significance.

The FDA Orange Book lists patents submitted by NDA holders for approved drug products. A patent is not automatically an Orange Book patent because it broadly describes a drug technology. Listing depends on an NDA submission, FDA listing rules, and the relationship between the patent claims and the approved product.[3]

For MRI contrast agents, Orange Book relevance is product-specific. A patent covering a particular formulation, method of use, or drug substance may be listed against an NDA. An expired foundational patent such as 5,560,903 does not create a present Paragraph IV barrier.

When does a generic applicant face Paragraph IV risk?

A generic applicant would not face a current Paragraph IV risk from Patent 5,560,903 because the patent has expired.

Historically, a Paragraph IV certification could have been relevant if:

The patent had been listed against the reference product;
The patent had not expired;
The abbreviated new drug application sought approval for a use or formulation covered by the patent; and
The applicant challenged validity, enforceability, or infringement.

Paragraph IV litigation typically concerns later, product-specific patents rather than broad foundational patents that expired years earlier. Current generic entry risk for gadolinium agents is more likely to arise from:

Later formulation patents;
Device or injector patents;
Manufacturing-process patents;
Use patents for specific organ imaging;
Pediatric exclusivity or other regulatory exclusivity;
Product-specific patent listings associated with newer agents.

What patent landscape surrounds gadolinium MRI contrast agents?

The historical MRI contrast-agent landscape developed through several patent layers.

Foundational chelation patents

Early patents covered the use of paramagnetic metal chelates as MRI contrast agents, including gadolinium complexes with aminopolycarboxylic ligands. These patents established the basic safety and imaging concept reflected in Patent 5,560,903.

Product-specific composition patents

Later patents focused on individual complexes, including:

Gadolinium-DTPA and its salts;
Gadolinium-DOTA and meglumine salts;
Gadobutrol;
Gadobenate;
Gadoxetate;
Gadodiamide;
Gadoversetamide.

These patents generally had narrower chemical claims and were more important to product launch timing than the broad method claims in Patent 5,560,903.

Macrocyclic versus linear chelates

Macrocyclic agents such as gadoterate, gadobutrol, and gadoteridol use more tightly encasing ligands than many earlier linear agents. Patent estates for these products typically emphasize:

Defined macrocyclic ligand structures;
Specific stereochemistry;
Salt forms;
Purity profiles;
Manufacturing conditions;
Pharmaceutical compositions;
Use in particular imaging protocols.

The patent at issue covers cyclic and acyclic chelating agents at a high level, but it does not provide the product-specific structural precision normally used to protect a modern commercial agent.

Formulation and manufacturing patents

Secondary patent protection may cover:

Low-metal-impurity formulations;
Control of free gadolinium;
Specific pH and osmolality;
Stabilizers and excipients;
Sterile manufacturing;
Container-closure systems;
Automated injection systems;
Production of high-purity macrocyclic complexes.

These patents can remain commercially relevant after core composition patents expire. They are separate from the expired claims of Patent 5,560,903.

How does Patent 5,560,903 compare with major MRI contrast-agent patents?

Technology	Relationship to Patent 5,560,903	Commercial significance
Gd-DTPA, Magnevist	Likely within the technical genus	Core product protection expired
Gd-DOTA, Dotarem	Within cyclic-chelate and Gd(III) concepts	Later product-specific protection controlled launch
Gadobutrol, Gadavist	Within Gd chelation concept	Macrocyclic structure and manufacturing patents were more relevant
Gadobenate, MultiHance	Within broad Gd-chelate scope	Product and use claims supplied commercial protection
Gadoxetate, Eovist	Within Gd-chelate and pharmaceutical-agent concepts	Liver-imaging use and product-specific rights mattered
Gadodiamide, Omniscan	Within Gd-chelate and nonionic concepts	Historical product-specific patents, now largely expired
Ferumoxytol	Uses iron oxide nanoparticles rather than a conventional small-molecule chelate	Different formulation and nanoparticle patent landscape

Patent 5,560,903 is broader in technical concept than most product patents but weaker as a current commercial asset because it is expired and lacks a defined molecular structure.

How strong were the claims from an infringement perspective?

The patent had meaningful historical breadth but several litigation vulnerabilities.

Strengths

Claims 1-3 cover a wide range of paramagnetic chelate methods.
Gd(III), Mn(II), iron, and Fe(II) are expressly identified.
Both cyclic and open-chain chelators are covered.
Ionic, nonionic, salt, and non-salt configurations are addressed.
Claims cover human use and multiple administration routes.
The formulation claims reach pharmaceutical agents rather than laboratory complexes alone.

Vulnerabilities

Claims 1-3 use functional terms such as "maintaining sufficient paramagnetism," "physiologically compatible," and "effective to enhance NMR imageability."
Claim 3 does not specify the chelating agent, metal, dose, imaging sequence, or pharmacokinetic threshold.
The broad genus claims could face written-description and enablement scrutiny if asserted against later-developed chelators with materially different chemistry.
A defendant could challenge whether a particular complex maintains the claimed paramagnetic behavior in the relevant physiological environment.
Method claims require proof that the accused party practiced the claimed method or induced its practice.
A product sale alone does not automatically establish direct infringement of a method claim under 35 U.S.C. § 271(a).[4]

The broadest claims would have been most valuable against early MRI contrast-agent developers. Later products could have contested infringement based on claim construction, enablement, written description, or differences in administration and imaging use.

What litigation and settlement risks remain?

There is no current litigation or settlement risk based on the expired claims of Patent 5,560,903.

Historical MRI contrast litigation generally centered on:

Product-specific patents;
Generic Abbreviated New Drug Applications;
Paragraph IV certifications;
Patent listing disputes;
Formulation and manufacturing patents;
Market-entry dates under settlement agreements.

An expired foundational patent can remain relevant in freedom-to-operate histories and validity analyses, but it cannot support a new injunction or damages claim for post-expiration conduct. Any surviving dispute would need to involve a separate patent, a pre-expiration period, or a distinct regulatory issue.

Are biosimilar risks relevant to this patent?

No. Biosimilar law is not the relevant pathway for the agents principally implicated by these claims.

Most conventional MRI contrast agents are small-molecule chemical drugs or defined coordination complexes. Generic applicants generally use the ANDA pathway under section 505(j), not the biologics license application pathway under the Biologics Price Competition and Innovation Act.[5]

Some iron-based products, including nanoparticle formulations, may raise complex-drug or product-specific comparability issues. That does not convert Patent 5,560,903 into a biosimilar patent, and the patent's claims do not cover a biologic.

What generic launch scenarios exist?

Because Patent 5,560,903 is expired, generic launch analysis turns on other rights and FDA requirements.

Scenario 1: Conventional gadolinium generic

A generic applicant targets an established gadolinium agent using an ANDA. The principal risks are product-specific patents, reference-product exclusivity, quality requirements, and demonstration of pharmaceutical equivalence.

Scenario 2: Alternative salt or formulation

A company develops a different counterion, pH, concentration, or excipient system. Patent 5,560,903 is unlikely to block launch, but later formulation patents may be relevant.

Scenario 3: New macrocyclic agent

A new macrocyclic gadolinium complex may fall within the expired technical teaching of the patent, but that does not create present infringement exposure. The relevant estate would consist of new composition, process, impurity-control, and use patents.

Scenario 4: Off-label paramagnetic agent

A product such as ferumoxytol may be used off-label for MRI. The regulatory and patent analysis differs because the product is approved for an anemia indication, and the imaging use may not be an approved labeling pathway.

What geographic coverage does the patent have?

U.S. Patent 5,560,903 had territorial effect only in the United States. Any corresponding foreign patent would require separate analysis of:

National-phase or direct foreign filings;
Grant status;
Patent-term adjustments;
Supplementary protection certificates;
Local claim scope;
Local litigation and opposition history.

Expiration of the U.S. patent does not establish expiration of corresponding European, Japanese, Canadian, or other national rights, although patents from the same mid-1990s family would generally also be expired by 2025.

Key Takeaways

U.S. Patent 5,560,903 covers broad methods for chelating paramagnetic ions while preserving paramagnetism and physiological compatibility.
Claims 1-3 are the core independent method claims.
Gadolinium(III), manganese(II), iron, and Fe(II) are expressly covered.
The claims reach both cyclic and acyclic chelators, including aminopolycarboxylic acids.
Dependent claims address salts, nonionic complexes, formulations, pH, concentration, routes, isotonicity, and water solubility.
The patent is expired. Its ordinary 17-year term from the 1996 grant would have ended in 2013.
It presents no current Paragraph IV, Orange Book, injunction, or generic-launch barrier.
It is not a biosimilar patent.
Current MRI contrast-agent risks arise from later product, formulation, manufacturing, device, and method-of-use patents.
The patent remains relevant as historical prior art and as a record of the broad technical foundation for paramagnetic MRI contrast agents.

FAQs

Does U.S. Patent 5,560,903 claim gadobutrol specifically?

No. It does not recite gadobutrol by name or claim its molecular structure. Gadobutrol could fall within the technical scope of the broad Gd(III) and cyclic-chelate concepts, but the patent does not provide product-specific protection for gadobutrol.

Could a company launch a gadolinium generic despite Patent 5,560,903?

Yes. The patent is expired. A launch would require review of current product-specific patents, FDA requirements, exclusivity, manufacturing rights, and any relevant Orange Book listings.

Does claim 23 cover standard 0.5 M gadolinium injection?

Not literally, based on the stated concentration. Claim 23 recites 5-250 mmol/L, while a 0.5 M solution contains approximately 500 mmol/L. Other claims do not contain that concentration limitation.

Does the patent cover MRI use of manganese and iron agents?

The claims expressly identify Mn(II), iron, and Fe(II). Coverage would still depend on satisfying the method, chelation, physiological-compatibility, and imageability limitations.

Can an expired patent still affect freedom-to-operate analysis?

Yes, as historical prior art and as evidence of disclosed technology. It cannot, however, support a current infringement claim after expiration. Current freedom to operate depends on unexpired patents and regulatory exclusivities.

References

United States Patent and Trademark Office. (1996). U.S. Patent No. 5,560,903. U.S. Department of Commerce.
United States Patent and Trademark Office. (2024). Patent term calculator and patent term guidance. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
35 U.S.C. §§ 154, 271.
U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug applications.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	31 29 906.7	Jul 24, 1981
Germany	33 02 410.3	Jan 21, 1983
Germany	34 01 052.1	Jan 11, 1984

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0071564	⤷ Start Trial	SPC/GB93/060	United Kingdom	⤷ Start Trial
Austria	18719	⤷ Start Trial
Austria	397465	⤷ Start Trial
Austria	52247	⤷ Start Trial
Austria	A19184	⤷ Start Trial
Australia	1018488	⤷ Start Trial
Australia	1018688	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,560,903